Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Combined With Daratumumab in Advanced Solid Tumors
NCT03098550Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label trial of daratumumab in triple-negative breast cancer (TNBC) and pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events (AEs) up to 34 months, Number of Participants With Serious Adverse Events (SAEs) up to 34 months and 3 more. Started Jun 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
triple-negative breast cancer (TNBC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03098550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098550.